Portage Historical Cash Flow
| PRTG Stock | USD 4.18 0.03 0.71% |
Analysis of Portage Biotech cash flow over time is an excellent tool to project Portage Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 0.0 or Total Cash From Financing Activities of 3.4 M as it is a great indicator of Portage Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Portage Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Portage Biotech is a good buy for the upcoming year.
Portage |
About Portage Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Portage balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Portage's non-liquid assets can be easily converted into cash.
Portage Biotech Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Portage Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Portage Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.At this time, Portage Biotech's Depreciation is most likely to increase significantly in the upcoming years. The Portage Biotech's current Other Non Cash Items is estimated to increase to about 71.3 M, while Free Cash Flow is forecasted to increase to (13.6 M).
Portage Biotech cash flow statement Correlations
Click cells to compare fundamentals
Portage Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Portage Biotech cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (3.0M) | (382K) | 20.6M | (12.8M) | (5.5M) | (5.2M) | |
| Free Cash Flow | (3.7M) | (3.3M) | (6.8M) | (12.1M) | (14.3M) | (13.6M) | |
| Change In Working Capital | (114K) | (744K) | (461K) | (10K) | 982K | 1.0M | |
| Begin Period Cash Flow | 6.2M | 3.2M | 2.8M | 23.4M | 10.5M | 11.1M | |
| Other Cashflows From Financing Activities | 1M | (1.2M) | (1.7M) | (1.1M) | (20K) | (19K) | |
| Other Non Cash Items | 1.5M | 1.4M | (670K) | 106.2M | 67.9M | 71.3M | |
| Total Cash From Operating Activities | (3.7M) | (4.3M) | (6.8M) | (12.1M) | (14.3M) | (13.6M) | |
| Net Income | (7.2M) | (17.2M) | (19.2M) | (104.7M) | (75.3M) | (71.6M) | |
| Total Cash From Financing Activities | 700K | 4.8M | 27.3M | (117K) | 6.0M | 3.4M | |
| End Period Cash Flow | 3.2M | 2.8M | 23.4M | 10.5M | 5.0M | 3.2M | |
| Stock Based Compensation | 2.2M | 8.8M | 9.1M | 4.3M | 2.6M | 3.4M | |
| Net Borrowings | (50K) | 700K | (2.0M) | (2M) | (1.8M) | (1.7M) | |
| Total Cashflows From Investing Activities | 5.7M | (446K) | (860K) | (617K) | (555.3K) | (527.5K) | |
| Change To Operating Activities | (281K) | (1.5M) | 229K | (1.1M) | (983.7K) | (934.5K) | |
| Change To Netincome | 1.5M | 12.2M | 10.6M | 92.5M | 106.4M | 111.8M | |
| Change To Liabilities | 167K | 880K | (1.2M) | 1.1M | 1.3M | 1.3M |
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (68.17) | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.